P59. Depleting the suppressors for the benefit of immunotherapy against cervical cancer

por Draghiciu, O, Hoogeboom, BN, Meijerhof, T, Nijman, HW, Daemen, CAHH
Publicado 2014

Immunologic aspect of ovarian cancer and p53 as tumor antigen

por Nijman, HW, Lambeck, A, van der Burg, SH, van der Zee, AGJ, Daemen, T
Publicado 2005

Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[(11)C]Methyl-AMD3465 PET

por Hartimath, SV, Draghiciu, O., Daemen, T, Nijman, H.W., van Waarde, A., Dierckx, R.A.J.O., de Vries, E.F.J.
Publicado 2019

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

por Wouters, MCA, Dijkgraaf, EM, Kuijjer, ML, Jordanova, ES, Hollema, H, Welters, MJP, van der Hoeven, JJM, Daemen, T, Kroep, JR, Nijman, HW, van der Burg, SH
Publicado 2015